Neulasta Sales Data
| Rank 9 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Neulasta U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 9 | $854,508 | -4.90% | 308 | -6.10% |
| Q3 2013 | 9 ( 1) |
$898,539 | 4.38% | 328 | 1.55% |
| Q2 2013 | 10 | $860,860 | 0.21% | 323 | -1.82% |
| Q1 2013 | 10 | $859,062 | 6.94% | 329 | 4.11% |
| Q4 2012 | 10 | $803,286 | -3.54% | 316 | -4.53% |
| Q3 2012 | 10 (1) |
$832,784 | -1.17% | 331 | -1.19% |
| Q2 2012 | 11 (2) |
$842,628 | -0.86% | 335 | 1.21% |
| Q1 2012 | 13 ( 1) |
$849,971 | 3.33% | 331 | 1.53% |
| Q4 2011 | 12 (2) |
$822,578 | 4.59% | 326 | 3.49% |
| Q3 2011 | 14 (1) |
$786,464 | -3.86% | 315 | -5.69% |
| Q2 2011 | 15 | $818,068 | 4.04% | 334 | 3.41% |
| Q1 2011 | 15 | $786,288 | n/a | 323 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
